research roi semaglutide Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study Flow chart summarizing study design.

Compelling evidence indicates that the cardiovascular benefits of GLP-1 receptor agonists (GLP-1RAs) extend beyond their anti-obesity and antidiabetic effects, involving direct cardiac mechanisms of action 2,18,42

[PubMed: 12066187] 233

Ongoing Clinical Trials Numerous questions remain under investigation, including: Long-term biological effects Extended safety profiles Pharmacodynamic characteristics Receptor-level adaptations Combination therapy applications As a result, ongoing clinical trials continue to generate new information regarding the compounds biological activity and potential future applications

More targets, deeper effect

This illustrates how a simple syringe misread at high concentrations can result in a dangerous overdose